Not harsh really. I think that C14 has Buckleys chance of achieving anything material. The biotech world has already passed judgement by showing no interest in BIT225.
At best they may get a trial run where BIT225 gets a chance in combination with another drug but that won't provide any meaningful funding for BIT.
C14 is a last ditch effort by BIT - and it is coming way too late in any case.
C14 would have already approached any contacts they have pushing BIT225 and would have already got any answers positive or negative.
I suspect that BIT is toast and this will be the last year of their existence - maybe their last financial year.
Very sad but maybe very predictable too. Bit needs to come clean.
BIT Price at posting:
1.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)